Cutaneous head and neck melanoma in OPTiM, a randomized phase 3 trial of talimogene laherparepvec versus granulocyte‐macrophage colony‐stimulating factor …
RHI Andtbacka, SS Agarwala, DW Ollila… - Head & …, 2016 - Wiley Online Library
RHI Andtbacka, SS Agarwala, DW Ollila, S Hallmeyer, M Milhem, T Amatruda, JJ Nemunaitis…
Head & neck, 2016•Wiley Online LibraryBackground Cutaneous head and neck melanoma has poor outcomes and limited treatment
options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma,
intralesional administration of the oncolytic virus talimogene laherparepvec improved
durable response rate (DRR; continuous response≥ 6 months) compared with
subcutaneous granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Methods
Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma …
options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma,
intralesional administration of the oncolytic virus talimogene laherparepvec improved
durable response rate (DRR; continuous response≥ 6 months) compared with
subcutaneous granulocyte‐macrophage colony‐stimulating factor (GM‐CSF). Methods
Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma …
Background
Cutaneous head and neck melanoma has poor outcomes and limited treatment options. In OPTiM, a phase 3 study in patients with unresectable stage IIIB/IIIC/IV melanoma, intralesional administration of the oncolytic virus talimogene laherparepvec improved durable response rate (DRR; continuous response ≥6 months) compared with subcutaneous granulocyte‐macrophage colony‐stimulating factor (GM‐CSF).
Methods
Retrospective review of OPTiM identified patients with cutaneous head and neck melanoma given talimogene laherparepvec (n = 61) or GM‐CSF (n = 26). Outcomes were compared between talimogene laherparepvec and GM‐CSF treated patients with cutaneous head and neck melanoma.
Results
DRR was higher for talimogene laherparepvec–treated patients than for GM‐CSF treated patients (36.1% vs 3.8%; p = .001). A total of 29.5% of patients had a complete response with talimogene laherparepvec versus 0% with GM‐CSF. Among talimogene laherparepvec–treated patients with a response, the probability of still being in response after 12 months was 73%. Median overall survival (OS) was 25.2 months for GM‐CSF and had not been reached with talimogene laherparepvec.
Conclusion
Treatment with talimogene laherparepvec was associated with improved response and survival compared with GM‐CSF in patients with cutaneous head and neck melanoma. © 2016 Wiley Periodicals, Inc. Head Neck 38: 1752–1758, 2016
Wiley Online Library